Mountain Crest Acquisition Corp II

Better Therapeutics, Inc. develops software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. It engages in developing a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. It offers software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced several key research milestones designed to advance and further validate its therapeutic technologies, including the first ever study of nCBT as potential treatment for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (

Better Therapeutics Announces Key Milestones and Updates for Ongoing Studies of its Digital Therapeutics Approach for Cardiometabolic Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in a fireside chat at Chardan's Virtual Prescription Digital Therapeutics Summit on Monday, April 11, 2022 at 1:30 p.m. Eastern Time. A live webcast will be available on the Presentatio

Better Therapeutics to Participate in Chardan's Virtual Prescription Digital Therapeutics Summit

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced its financial results for the fourth quarter and full year ending December 31, 2021. These results follow the recent announcement of positive primary endpoint data from the pivotal clinical trial for the company's BT-001 prescription digital th

Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will hold a call this Friday, March 25, to provide a deeper look at the results from the company's pivotal clinical trial for BT-001, a prescription digital therapeutic for type 2 diabetes. Last week, the company shared

Better Therapeutics to Host Call Detailing Promising Results from Pivotal Clinical Trial for Type 2 Diabetes Digital Therapeutics

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced primary endpoint data from its pivotal trial of BT-001, a first-in-class investigational PDT platform that is designed to use digitally delivered nCBT to treat type 2 diabetes. The open label, randomized, controlled, parallel g

Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in collaboration with MedEd On The Go, today announced the availability of an on-demand, educational symposium entitled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.” The on-demand educational symposium is moderate

Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, announces a new code from the Center for Medicare and Medicaid Services (CMS) that paves the way for reimbursement of these therapies. CMS recently created new, Level II Healthcare Common Procedure Coding Systems (HCPCS) codes for prescription digital beha

Better Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies (PDTs)

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, today announced the first patient has been enrolled in a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-00

Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows: A virtual fireside chat hosted by LifeSci Capital on January 26 from 12 – 1 p.m. EST. The management team will discuss the cu

Better Therapeutics to Participate in Two Upcoming Investor Events

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress. “We've made excellent progress since debuting as a public company,” said Kevin Appelbaum, co-founder and chief executive officer of Better Therapeutics. “Our clinical development pipeline across multiple product can

Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022

Better Therapeutics has developed a proprietary platform for creating FDA-regulated, software-based solutions for cardiometabolic diseases.

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti Sodhi Jaggi, PharmD, as its Chief Strategy Officer. “Deepti has spent her career driving innovation at the intersection of healthcare and technology,” said Kevin Appelbaum, co-founder and Chief Executive Officer. “She br

Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy Officer

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of patient enrollment in its potentially pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of type 2 diabetes. BT-001 is being developed as an FDA-regulated, prescription digital therapeutic that deliver

Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Major General Elder Granger, M.D., U.S. Army (retired) to its board of directors. “Dr. Granger's track record of leadership in navigating complex policy, regulatory and competitive environments will be welcome additions to the

Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors

GlobalFoundries

Lottery.com

NerdWallet

Rent the Runway

Vivid Seats

Warby Parker

With 2021 proving to be the year of compelling IPOs, here are some new stocks to consider if you're feeling in a risk-on mood. The post 7 New Stocks That Can Provide Long-Term Gains After Their IPOs appeared first on InvestorPlace.

7 New Stocks That Can Provide Long-Term Gains After Their IPOs

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Thiago Licias de Oliveira as its Chief People Officer. In this newly created role, Thiago will develop and implement a people strategy to build, structure and retain an exceptional team through a period of anticipated high grow

Better Therapeutics Appoints Thiago Licias de Oliveira as Its Chief People Officer

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in collaboration with Mass General Brigham, today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001, a PDT delivering nutritional cognitive behavioral therapy

Mass General Brigham Joins Better Therapeutics in Real World Evidence Study Collaboration

Better Therapeutics (BTTX) stock is surging higher on Monday after completing its SPAC merger with Mountain Crest Acquisition Corp II. The post Better Therapeutics SPAC Merger: 8 Things for BTTX Stock Investors to Know appeared first on InvestorPlace.

Better Therapeutics SPAC Merger: 8 Things for BTTX Stock Investors to Know

SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)---- $BTTX--Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of its business combination with Mountain Crest Acquisition Corp II (Nasdaq: MCAD; “Mountain Crest II”), a publicly traded special purpose acquisition corporation or SPAC. The resulting combined company will commence trading its shares on Nasdaq under

News for Mountain Crest Acquisition Corp II Stock (BTTX)